NewAmsterdam Pharma (NAMS) shares were down 1% on Thursday after reporting a Q1 net loss of $0.34 per diluted share, narrowing from a $1.06 loss a year earlier.
Analysts polled by FactSet expected a $0.50 loss.
Revenue for the quarter ended March 31 was $3 million, up from $1.4 million a year earlier.
Analysts expected $1.6 million.
The Dutch biopharmaceutical company had cash and equivalents of $808.5 million at end of Q1 compared with $834.2 million on hand on Dec. 31, 2024.
Price: 18.08, Change: -0.84, Percent Change: -4.44
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。